Whole-cell and acellular pertussis vaccination programs and rates of pertussis among infants and young children

CMAJ. Canadian Medical Association Journal

Volumn 175, Issue 10, 2006, Pages 1213-1217

  Vickers, David ^a,b   Ross, Allen G ^b,c   Mainar Jaime, Raúl C ^b   Neudorf, Cordell ^c   Shah, Syed ^b  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c SASKATOON HEALTH REGION   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; PERTUSSIS VACCINE;

ARTICLE; CONTROLLED STUDY; HEALTH CARE PERSONNEL; HEALTH SURVEY; HUMAN; IMMUNIZATION; INCIDENCE; PERTUSSIS; PRESCHOOL CHILD; SCHOOL CHILD; VACCINATION;

EID: 33751233861     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.051637     Document Type: Article

References (32)

1. Public Health Agency of Canada. Pertussis. Vaccine-preventable diseases. Available: www.phac-aspc.gc.ca/im/vpd-mev/pertussis_e.html (accessed 2006 Sept 7).
2. Tan T, Halperin S, Cherry JD, et al. Pertussis immunization in the Global Pertussis Initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005;24:S83-6.
3. Bentsi-Enchill AD, Halperin SA, Scott J, et al. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997;15:301-6.
4. Gustafsson L, Hallander HO, Reizenstein E, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
5. Mortimer EA, Cherry JD. Pertussis (whooping cough). In: Gershon AA, Hotez PJ, Katz SL, editors. Krugman's infectious diseases of children. Philadelphia: Mosby; 2004. p. 443-59.
6. Lacombe K, Yam A, Simondon K, et al. Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children. Vaccine 2004;23:623-8.
7. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15:1606-12.
8. Bisgard KM, Rhodes P, Connelly BL, et al. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001. Pediatrics 2005;116:e285-94.
9. Lugauer S, Heininger U, Cherry JD, et al. Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 2002;161:142-6.
10. Hviid A, Stellfeld M, Andersen PH, et al. Impact of routine vaccination with a pertussis toxoid vaccine in Denmark. Vaccine 2004;22:3530-4.
11. Olin P, Gustafsson L, Barreto L, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003;21:2015-21.
12. McWha L, MacArthur A, Badiani T, et al. Measuring up: results from the National Immunization Coverage Survey, 2002. Can Commun Dis Rep 2004;30:37-50.
13. Vickers D. The epidemiology and transmission of pertussis in the Saskatoon Regional Health Authority: 1995 to 2003 [thesis]. Saskatoon: University of Saskatchewan; 2005.
14. Szklo M, Nieto FJ. Measuring disease occurrence. In: Epidemiology: beyond the basics. Gaithersburg (MD): Aspen Publishers, Inc.; 2000. p. 55-87.
15. Kleinbaum DG, Kupper LL, Muller KE, et al. Poisson regression. In: Kugushev A, editor. Applied regression analysis and other multivariate methods. 3rd ed. Pacific Grove: Duxbury Press; 1998. p. 687-709.
16. De Serres G, Shadmani R, Boulianne N, et al. Effectiveness of a single dose of acellular pertussis vaccine to prevent pertussis in children primed with pertussis whole cell vaccine. Vaccine 2001;19:3004-8.
17. Newman SC. Age-period-cohort analysis. In: Biostatistical methods in epidemiology. New York: Wiley Interscience; 2001. p. 258-62.
18. Strathdee SA, Loughlin AM. Vaccines: past, present, and future. In: Nelson KE, Williams CM, Graham NMH, editors. Infectious disease epidemiology. Gaithersburg (MD): Aspen Publishers, Inc.; 2001. p. 255-80.
19. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997:100:772-88.
20. Halperin S, Scheifele D, Barreto L, et al. Comparison of a fifth dose of a five-component acellular or a whole-cell pertussis vaccine in children four to six years of age. Pediatr Infect Dis J 1991;18:772-9.
21. Lavigne MV, Castro M, Mateo N, et al. Whole-cell Bordetella pertussis vaccine component modulates the mouse immune response to an unrelated soluble antigen. Microbes Infect 2002;4:815-20.
22. Mills KH, Ryan M, McGuirk P, et al. The immunology of Bordetella pertussis infection. Biologicals 1999;27:77.
23. Langue J, Matisse N, Pacoret P, et al. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of a second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine 2004;22:1406-14.
24. Mäkinen J, Mertsola J, Mooi FR, et al. Bordetella pertussis isolates, Finland. Emerg Infect Dis 2005;11:183-4.
25. Mooi FR, van Oirschot H, Heuvelman H, et al. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998;66:670-5.
26. Giesecke J. Modern infectious disease epidemiology. London (UK): Arnold; 2002.
27. Pentacel [product monograph]. Toronto: Sanofi-Pasteur. Available: www .sanofipasteur.ca|sanofi-pasteur-ca/front/templates/index.jsp?codeRubrique= 53&lang =EN (accessed 2006 Sept 7).
28. Pebody RG, Gay NJ, Giammanco A, et al. The seroepidemiology of Bordetella pertussis infection in Western Europe. Epidemiol Infect 2005;133:159-71.
29. Elahi S, Brownlie R, Korzeniowski J, et al. Infection of newborn piglets with Bordetella pertussis: a new model for pertussis. Infect Immun 2005;73:3636-45.
30. Gerdts V, Tsang C, Griebel PJ, et al. DNA vaccination in utero: a new approach to induce protective immunity in the newborn. Vaccine 2004;22:1717-27.
31. Gerdts V, Snider M, Brownlie R, et al. Oral DNA vaccination in utero induces mucosal immunity and immune memory in the neonate. J Immunol 2002;168:1877-85.
32. Gerdts V, Babiuk LA, van Drunen Littel-van den Hurk, et al. Fetal immunization by a DNA vaccine delivered into the oral cavity. Nat Med 2000;6:929-32.